[1. Srivastava A, Brewer AK, Mauser-Bunschoten EP, et al. Guidelines for the management of hemophilia. Haemophilia 2013; 19(1): e1-47.10.1111/j.1365-2516.2012.02909.x]Open DOISearch in Google Scholar
[2. Pai M, Key NS, Skinner M, et al. NHF-McMaster guideline on care models for haemophilia management. Haemophilia 2016; 22 (Suppl. 3): 6-16.10.1111/hae.13008]Search in Google Scholar
[3. Yeung C, Santesso N, Zeraatkar D, et al. Integrated multidisciplinary care for the management of chronic conditions in adults: an overview of reviews and an example of using indirect evidence to inform clinical practice recommendations in the field of rare disease. Haemophilia 2016; 22 (Suppl. 3): 41-50.10.1111/hae.13010]Open DOISearch in Google Scholar
[4. Kaupp MJ, Säilä H, Belt EA, Hakala M. Beware of the biologicals - hospitals may die: the Rheumatism Foundation Hospital, Heinola, Finland (1951-2010). Clin Rheumatol 2012; 31(8): 1151-4.10.1007/s10067-012-2001-9]Search in Google Scholar
[5. The King’s Fund. Haywood Rheumatology Centre - case study. October 2014. Available from https://www.kingsfund.org.uk/sites/files/kf/media/haywood-rheumatology-centrekingsfund-oct14.pdf (accessed 14 November 2016).]Search in Google Scholar
[6. Väre P. Nikophorou E, Hannonen P, Sokka T. Delivering a one-stop, integrated, and patient-centred service for patients with rheumatic diseases. SAGE Open Med 2016; 14:4. doi: 10.1177/2050312116654404.]Search in Google Scholar
[7. Corey M, McLaughlin FJ, Williams M, Levison H. A comparison of survival, growth and function in patients with cystic fibrosis in Boston and Toronto. J Clin Epid 1988; 41(6): 583-91.10.1016/0895-4356(88)90063-7]Search in Google Scholar
[8. Cystic Fibrosis Foundation. Cystic Fibrosis Foundation Patient Registry 2011 Annual Data Report. Bethesda, Maryland: Cystic Fibrosis Foundation, 2012. Available from http://www.cysticfibrosisdata.org/ReportsUS.html (accessed 14 November 2016).]Search in Google Scholar
[9. Hay C. The UK haemophilia database: a tool for research audit and healthcare planning. Haemophilia 2004; 10: 21-25.]Search in Google Scholar
[10. Makris M, Calizzani G, Fischer K, et al. EUHASS: The European Haemophilia Safety Surveillance system. Thromb Res 2011; 127 (Suppl. 2): 22-25.10.1016/S0049-3848(10)70150-X]Search in Google Scholar
[11. Astermark J. Inhibitor development: patient-determined risk factors. Haemophilia 2010; 16(102): 66-70.10.1111/j.1365-2516.2008.01923.x19298384]Search in Google Scholar
[12. Chambost H. Assessing risk factors prevention of inhibitors in haemophilia. Haemophilia 2010; 16 (Suppl. 2): 10-15.10.1111/j.1365-2516.2009.02197.x20132333]Open DOISearch in Google Scholar
[13. Franchini M, Tagliaferri A, Mannucci PM. The management of haemophilia in elderly patients. Clin Interv Aging 2007; 2(3): 361-8.]Search in Google Scholar
[14. Franchini M, Mannucci PM. Past, present and future of hemophilia: a narrative review. Orphanet J Rare Dis 2012; 7:24.10.1186/1750-1172-7-24350260522551339]Search in Google Scholar
[15. Mannucci PM, Mauser-Bunschoten EP. Cardiovascular disease in haemophilia patients: a contemporary issue. Haemophilia 2010; 16 (Suppl. 3): 58-66.10.1111/j.1365-2516.2010.02262.x20586804]Open DOISearch in Google Scholar
[16. Coppola A, Tagliaferri A, Franchini M. The management of cardiovascular diseases in patients with hemophilia. Semin Thromb Hemost 2010; 36: 91-102.10.1055/s-0030-124872820391300]Open DOISearch in Google Scholar
[17. Peyvandi F, Palla R, Menegatti M, et al. Coagulation factor activity and clinical bleeding severity in rare bleeding disorders: results from the European Network of Rare Bleeding Disorders. J Thromb Haemost 2012; 10(4): 615-21.10.1111/j.1538-7836.2012.04653.x22321862]Open DOISearch in Google Scholar